Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 2 and 3
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jung, Y.K. | - |
dc.date.accessioned | 2021-09-04T08:51:10Z | - |
dc.date.available | 2021-09-04T08:51:10Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 1598-9992 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/91386 | - |
dc.description.abstract | Ever since direct-acting antiviral agents (DAA) have been approved and released into the world, numerous studies on the efficacy, adverse effects and drug-drug interactions of interferon-free DAA combination therapy have been studied and published. With all oral DAA therapy showing sustained virological response rate of 80-90% with minimal adverse events, HCV eradication has now become a realistic goal. DAA combination treatments were approved and adapted to practice in Korea in 2015, and Korean Association for the Study of the Liver (KASL) has revised the guideline based on the systematic approach that reflects evidence-based medicine and expert opinions. In this article, new recommendations for treatment of chronic HCV genotype 2 and 3 infected patients will be introduced base on KASL practice guidelines for management of hepatitis C that has been updated in 2015. | - |
dc.language | Korean | - |
dc.language.iso | ko | - |
dc.subject | alpha interferon | - |
dc.subject | antivirus agent | - |
dc.subject | ribavirin | - |
dc.subject | sofosbuvir | - |
dc.subject | combination drug therapy | - |
dc.subject | genetics | - |
dc.subject | genotype | - |
dc.subject | Hepacivirus | - |
dc.subject | hepatitis C | - |
dc.subject | human | - |
dc.subject | isolation and purification | - |
dc.subject | practice guideline | - |
dc.subject | South Korea | - |
dc.subject | virology | - |
dc.subject | Antiviral Agents | - |
dc.subject | Drug Therapy, Combination | - |
dc.subject | Genotype | - |
dc.subject | Hepacivirus | - |
dc.subject | Hepatitis C | - |
dc.subject | Humans | - |
dc.subject | Interferon-alpha | - |
dc.subject | Practice Guidelines as Topic | - |
dc.subject | Republic of Korea | - |
dc.subject | Ribavirin | - |
dc.subject | Sofosbuvir | - |
dc.title | Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 2 and 3 | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Jung, Y.K. | - |
dc.identifier.doi | 10.4166/kjg.2016.67.3.132 | - |
dc.identifier.scopusid | 2-s2.0-85015353183 | - |
dc.identifier.bibliographicCitation | The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, v.67, no.3, pp.132 - 136 | - |
dc.relation.isPartOf | The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi | - |
dc.citation.title | The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi | - |
dc.citation.volume | 67 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 132 | - |
dc.citation.endPage | 136 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.identifier.kciid | ART002091740 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordPlus | alpha interferon | - |
dc.subject.keywordPlus | antivirus agent | - |
dc.subject.keywordPlus | ribavirin | - |
dc.subject.keywordPlus | sofosbuvir | - |
dc.subject.keywordPlus | combination drug therapy | - |
dc.subject.keywordPlus | genetics | - |
dc.subject.keywordPlus | genotype | - |
dc.subject.keywordPlus | Hepacivirus | - |
dc.subject.keywordPlus | hepatitis C | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | isolation and purification | - |
dc.subject.keywordPlus | practice guideline | - |
dc.subject.keywordPlus | South Korea | - |
dc.subject.keywordPlus | virology | - |
dc.subject.keywordPlus | Antiviral Agents | - |
dc.subject.keywordPlus | Drug Therapy, Combination | - |
dc.subject.keywordPlus | Genotype | - |
dc.subject.keywordPlus | Hepacivirus | - |
dc.subject.keywordPlus | Hepatitis C | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | Interferon-alpha | - |
dc.subject.keywordPlus | Practice Guidelines as Topic | - |
dc.subject.keywordPlus | Republic of Korea | - |
dc.subject.keywordPlus | Ribavirin | - |
dc.subject.keywordPlus | Sofosbuvir | - |
dc.subject.keywordAuthor | Antiviral agents | - |
dc.subject.keywordAuthor | Chronic hepatitis C | - |
dc.subject.keywordAuthor | Evidence-based medicine | - |
dc.subject.keywordAuthor | Genotype | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.